一线化疗方案治疗广泛期小细胞肺癌的网状meta分析

背景与目的顺铂/卡波联合伊立替康/依托泊苷双药化疗方案被推荐为治疗广泛期小细胞肺癌（small cell lung cancer of extensive disease, ED-SCLC）的一线化疗方案。我们在网状meta分析中，通过合成直接证据和间接证据，对推荐的化疗方案的短期疗效进行排序。方法我们在EMBASE、PubMed、CENTARL及clinicaltrial.gov数据库检出了相关疗效比较的随机对照试验。ROB工具被用于评估纳入研究的质量， Stata 13.1被用于统计学合成。结果该研究共纳入10项随机对照研究，共计2,378名患者。与依托泊苷联合卡铂相比，肿瘤的完全缓解率（...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 19; no. 4; pp. 184 - 191
Main Author 陈玉洁 陈凌霄 钟殿胜 王竞 彭李娜 冯鑫
Format Journal Article
LanguageChinese
Published 天津医科大学总医院肿瘤科,天津,300052%天津医科大学总医院骨科,天津,300052%300052天津，天津医科大学总医院，天津市肺癌研究所 2016
Subjects
Meta分析
一线化疗
小细胞肺癌
Small cell lung cancer
First-line chemotherapy
小细胞肺癌
Meta分析
一线化疗
Meta-analysis
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2016.04.02

Cover

More Information
Summary:背景与目的顺铂/卡波联合伊立替康/依托泊苷双药化疗方案被推荐为治疗广泛期小细胞肺癌（small cell lung cancer of extensive disease, ED-SCLC）的一线化疗方案。我们在网状meta分析中，通过合成直接证据和间接证据，对推荐的化疗方案的短期疗效进行排序。方法我们在EMBASE、PubMed、CENTARL及clinicaltrial.gov数据库检出了相关疗效比较的随机对照试验。ROB工具被用于评估纳入研究的质量， Stata 13.1被用于统计学合成。结果该研究共纳入10项随机对照研究，共计2,378名患者。与依托泊苷联合卡铂相比，肿瘤的完全缓解率（complete remission rate, CR）在伊立替康联合卡铂组明显提高（OR=3.33,95%CI：1.47-7.54, P〈0.05）。伊立替康联合卡铂治疗后CR明显优于依托泊苷联合顺铂（OR=4.09,95%CI：1.18-14.12, P〈0.05）。结论本研究结果显示：伊立替康联合卡铂一线治疗ED-SCLC的疗效优于依托泊苷。
Bibliography:Background and objective Regimens that combine irinotecan or etoposide with cisplatin or carbo-platin have been recommended as ifrst-line regimen for extensive-disease small cell lung cancer （ED-SCLC）. In our network meta-analysis, we synthesized the direct and indirect lines of evidence to rank the short-term effcacies of these recommended chemotherapy regimens. Methods We searched databases, including EMBASE, PubMed, CENTARL and clinicaltrial.gov, for relevant randomized controlled trials （RCTs） that compared the effcacies of these treatments. A risk of bias tool was used to evaluate the quality of the included studies, whereas Stata 13.1 was used for statistical synthesis. Results Our study included 10 RCTs that involved 2,378 patients. Compared with that of the regimen that combined etoposide and carboplatin, the complete remission rate was signiifcantly higher in the group treated with irinotecan combined with carboplatin. hTe effcacy of the regi-men that combined irinotecan with carboplatin was signiifc
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2016.04.02